LOBESITY INVESTORS

lobesity-investors-logo

Lobesity Investors is a pharmaceutical company that specializes in providing pharmaceutical products designed to cure obesity. Its driven by its mission is the development of innovative therapies to treat obesity and either related disorders.

#SimilarOrganizations #People #Website #More

LOBESITY INVESTORS

Industry:
Health Care Health Diagnostics Pharmaceutical

Founded:
2015-01-01

Address:
Beachwood, Ohio, United States

Country:
United States

Website Url:
http://www.lobesitypharma.com

Total Employee:
11+

Status:
Active

Total Funding:
722.5 K USD

Technology used in webpage:
Domain Not Resolving


Similar Organizations

celator-pharmaceuticals-logo

Celator Pharmaceuticals

Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.

Current Employees Featured

not_available_image

Michael Boylan
Michael Boylan Co-Founder & Chief Scietific Officer @ Lobesity Investors
Co-Founder & Chief Scietific Officer

not_available_image

Daniel Lewis
Daniel Lewis Chief Executive Officer @ Lobesity Investors
Chief Executive Officer

not_available_image

Michael Wolfe
Michael Wolfe Co-Founder & Chief Medical Officer @ Lobesity Investors
Co-Founder & Chief Medical Officer

Founder


not_available_image

Michael Boylan

not_available_image

Michael Wolfe

Official Site Inspections

http://www.lobesitypharma.com

  • Host name: 199.59.243.228
  • IP address: 199.59.243.228
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Lobesity Investors"

Lobesity Company Profile 2024: Valuation, Investors ... - PitchBook

Developer of pharmaceutical products designed to prevent obesity. The company engages in the development and discovery of therapies for non-alcoholic fatty liver disease, hepatic steatosis, …See details»

Lobesity Company Profile | Management and Employees List

Www.lobesitypharma.com Lobesity Profile and History Lobesity Pharmaceuticals and Technologies, Inc. is focused on the clinical and commercial development of breakthrough …See details»

Lobesity Company Profile - Office Locations, Competitors ... - Craft

Lobesity (also known as Lobesity Investors) is a company engaged in the clinical and commercial development of therapies to treat obesity and related disorders. It provides its proprietary anti …See details»

Lobesity | Ohio Life Sciences

Lobesity is focused on the clinical and commercial development of breakthrough therapies for obesity and other related disorders. Founded in 2015 by researchers M Michael Wolfe MD and …See details»

Lobesity - Overview, News & Similar companies | ZoomInfo.com

View Lobesity (www.lobesitypharma.com) location in Ohio, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»

Lobesity Investors - Crunchbase Company Profile & Funding

Lobesity Investors is a pharmaceutical company that specializes in providing pharmaceutical products designed to cure obesity. Its driven by its mission is the development of innovative …See details»

Lobesity - VentureRadar

Website: https://lobesitypharma.com/ Develops a humanized monoclonal antibody targeting GIP to decrease nutrient absorption and storage, safely treating obesity without affecting appetite. …See details»

9 Meters Biopharma acquires anti-GIP monoclonal antibody from …

Jul 19, 2021 · 9 Meters Biopharma (NASDAQ:NMTR) has acquired global development rights to a proprietary and highly specific humanized monoclonal antibody (mAb), LOB-0136 (now known …See details»

www.lobesitypharma.com

Www.lobesitypharma.comSee details»

Experimental obesity drug packs double punch to reduce weight

May 15, 2024 · With obesity drugs now helping people to slim down, researchers are working to capitalize on their popularity by bulking up the weight-loss drug pipeline.See details»

Obesity drug success sparks buying spree in the biotech market

Sep 28, 2023 · At the beginning of August, the company announced it would be snapping up obesity drug developer Inversago Pharma in a $1.075 billion dollar deal, which includes …See details»

A revolution in obesity treatment | Nature Medicine

Sep 21, 2023 · Several incretin (gut-secreted hormone) pathways are now being explored therapeutically for obesity, diabetes and other obesity-related metabolic conditions (for …See details»

Game-changing obesity drugs go mainstream: what scientists are …

May 23, 2023 · Studies tackle who’s most likely to lose weight on the new generation of anti-obesity medications. US demand for weight-loss drug Wegovy has been so strong that its …See details»

A look at the R&D landscape in obesity, led by GLP-1s - Fierce …

Mar 19, 2024 · Several Big Pharmas are trying their hand in the space, with names like AstraZeneca, Bristol Myers Squibb, Novartis and Amgen touting early-stage assets in obesity. …See details»

Big Pharma targets $50bn obesity drugs market as demand booms

Nov 21, 2022 · Analysts forecast obesity medication is the next blockbuster pharma category, equivalent to the revolution in treating high blood pressure in the 1980s. “With conservative …See details»

Weight Loss Drugs Boost Obesity Market Value | Morgan Stanley

Sep 6, 2023 · Discover why new obesity medications have become a blockbuster drug category and the factors that could propel further growth in the rapidly-growing market.See details»

Obesity-drug pioneers win prestigious Lasker Award for medical …

Sep 19, 2024 · Three scientists are honoured for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way? Joel Habener (from left), Svetlana Mojsov and Lotte Bjerre …See details»

Obesity: New ways pharma is fighting a global epidemic

Feb 14, 2023 · Drug innovations aimed at helping obese adults manage their weight are coming to market, led by Danish multinational Novo Nordisk (Nordisk) and U.S.-based Eli Lilly (Lilly). …See details»

9 Meters Biopharma, Inc. (NASDAQ: NMTR) Broadens its Existing …

Jul 27, 2021 · Its latest candidate, a Phase 2 trial for short bowel syndrome (SBS), is vurolenatide, a proprietary long-acting GLP-1 agonist. The clinical-stage company has made a new move; …See details»

What is the pipeline for future medications for obesity?

Feb 1, 2024 · In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we …See details»

linkstock.net © 2022. All rights reserved